GSK_WRN4
GSK_WRN4 is an orally active WRN helicase inhibitor (pIC50=7.6) . GSK_WRN4 induces DNA damage markers (p21, p-γH2AX, p-KAP1) . GSK_WRN4 selectively inhibits microsatellite-unstable tumor growth in vitro and in vivo by inducing DNA double-strand breaks, particularly at expanded TA repeats and regions of DNA damage[1].
Product Specifications
CAS Number
2923008-66-4
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gsk-wrn4.html
Purity
98.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NC(C2CCCCC2)=CC=C1C(N[C@@H]3C=CS(=O)(C3)=O)=O
Molecular Formula
C16H20N2O4S
Molecular Weight
336.41
References & Citations
[1]Picco, et al. "Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells." Cancer Discovery 14.8 (2024) : 1457-1475.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 8/18 (C-51), CF594 conjugate, 0.1mg/mL
ACTH (Adrenocorticotrophic Hormone) (AH26), CF640R conjugate, 0.1mg/mL
Major Vault Protein (MVP) (1014), CF405S conjugate, 0.1mg/mL
